skip to main content

Non-Hodgkin Lymphoma

U-M Rogel Cancer Center first in Michigan to offer all FDA approved CAR T-cell therapies

Media contact: Jessica Webster-Sendra734-764-2220 |  Patients may contact Cancer AnswerLine, 800-865-1125

ANN ARBOR, Michigan — With the recently announced FDA approval of Kymriah to treat adults with lymphoma, the University of Michigan Rogel Cancer Center is the first center in Michigan to offer all currently available CAR T-cell therapies.

Childhood and Young Adult Cancer Survivors and Sex

When an adolescent or young adult undergoes cancer treatment, the goal is to become cancer-free and move on to live a healthy, productive life. But after treatment ends, it’s not always so simple. A new study looked at issues related to sexual functioning in young adults treated for cancer and found both men and women reported difficulties related to sex for up to two years after diagnosis

What cancer patients should know about preserving fertility

Ask Molly Moravek, M.D., why she pursued a career in fertility preservation for cancer patients, and she’ll tell you that it’s because her heart breaks every time she sees a patient who has had her fertility taken from her. It's why she built a program in partnership with Michigan Medicine’s Center for Reproductive Medicine and Rogel Cancer Center that works with patients facing treatment and their oncologists to preserve the patients’ opportunity to have children once they are healthy.

Defending with Discipline

Barbara Hilija Spiessl, a fifth-degree black belt in Taekwon-Do, was diagnosed with subcutaneous panniculitislike T-cell lymphoma, a rare subtype that accounts for less than 1 percent of all non-Hodgkin lymphomas. During her treatment and recovery, Spiessl called upon her Taekwon-Do training to find the strength and resilience to manage the long-term side effects from treatment.